Novartis Receives Final EMA Approval for Pluvicto, a Radioligand Therapy for Prostate Cancer
European Market Authorization and Regulatory Milestone
The European Medicines Agency (EMA) has granted final marketing authorization for Pluvicto (lutetium (177Lu) vipivotide tetraxetan) from Novartis (NVS), a radioligand therapy for prostate cancer. This approval is indicated for adult patients with metastatic castration-resistant prostate cancer (mCRPC) who have had prior treatment with androgen receptor pathway inhibitors and taxane-based chemotherapy. Following FDA approval in March 2022, Pluvicto has now secured access to the European market, solidifying its position as a global standard of care.
Efficacy Demonstrated in the VISION Phase 3 Trial
This European approval is based on the successful results of the global Phase 3 VISION trial (NCT03511664). The trial demonstrated that Pluvicto, in combination with standard of care (SoC), reduced the risk of death by 38% (HR 0.62) compared to SoC alone, as measured by overall survival (OS). The study also showed a 60% reduction in the risk of disease progression or death (HR 0.40) in terms of radiographic progression-free survival (rPFS).
Differentiated Targeted Radioligand Therapy (RLT) Technology
Pluvicto is a radioligand therapy (RLT) that targets prostate-specific membrane antigen (PSMA), a protein found on the surface of prostate cancer cells. The radioligand delivers the radioactive isotope lutetium-177 (177Lu) directly to the tumor cells, minimizing damage to healthy tissue. Unlike first-generation therapies like Bayer's Xofigo, which primarily target bone metastases, Pluvicto utilizes molecular targeting technology to treat even microscopic metastatic lesions, ushering in a new era of radiopharmaceuticals.
Market Expansion and Global Commercial Impact
Novartis acquired the Pluvicto pipeline through the acquisition of Endocyte in 2018 for $2.1 billion and has since made significant investments. Industry analysts predict that Pluvicto's global peak annual sales will exceed $5 billion, making it the first radiopharmaceutical to achieve multi-blockbuster status. The speed of market penetration will depend on factors such as the establishment of radioisotope production infrastructure in European hospitals and the reimbursement status of Pluvicto in various European countries.
Pluvicto's EMA approval, based on the Phase 3 VISION trial (38% reduction in OS risk, 60% reduction in rPFS risk), overcomes the limitations of existing chemotherapy and enzalutamide, reshaping the mCRPC treatment paradigm with targeted radioligand therapy (RLT). This approval validates Novartis's 2018 acquisition of Endocyte for $2.1 billion, significantly enhancing the commercial viability of Pluvicto's global peak sales exceeding $5 billion. In the short term, the speed of reimbursement negotiations in major European countries and the stability of the lutetium-177 supply chain will be key determinants of performance. In the medium to long term, staying ahead of competitors like Eli Lilly (through the acquisition of Point Biopharma) and expanding indications to earlier stages, such as metastatic hormone-sensitive prostate cancer (mHSPC), will be crucial for corporate value reevaluation. This approval marks a regulatory milestone, demonstrating that radiopharmaceuticals are not just next-generation technology but a core component of the vast precision oncology market.
Source: EMA (ema)